Braveheart Bio BRVE

R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

EPS, diluted: Q1 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY26: share-days: the 6-month average less the second quarter's.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Companies in Drug Manufacturers - General nearest Braveheart Bio's size, closest first.

Company	Market cap	PE	Its 10y median PE	Fwd PE	P/S	Revenue growth	Net margin
BRVEBraveheart Bio	$1.9B	n/m	n/a		n/m	n/m	n/m
HRMYHarmony Biosciences	$2.1B	11.7×	13.8×		2.2×	+24%	18.9%
ANIPANI Pharmaceuticals	$1.7B	15.4×	60.6×		1.7×	+31%	11.1%
PBHPrestige Consumer Healthcare	$2.3B	13.4×	15.3×		2.0×	−1%	15.6%
PAHCPhibro Animal Health	$1.6B	15.9×	21.5×		1.0×	+17%	6.6%
ANABAnaptysbio	$1.5B	10.7×	100.0×		n/m	n/m	n/m
PCRXPacira BioSciences	$1.5B	104×	65.6×		1.9×	+6%	2.0%
NRIXNurix Therapeutics	$2.8B	11.0×	10.8×		3.9×	n/m	42.0%
OMEROmeros	$1.2B	10.9×	11.7×		n/m	n/m	n/m
AMPHAmphastar Pharmaceuticals	$1.1B	14.8×	20.6×		1.5×	+1%	10.8%
OGNOrganon	$3.6B	17.9×	5.9×		0.6×	−2%	3.4%
Peer median	$1.6B	14.1×	17.9×		1.8×	+6%	10.9%

Its groups

• Drug Manufacturers - General
• Healthcare

Industry

Drug Manufacturers - General

Sector

Healthcare